Vapotherm, Inc. Stock

Equities

VAPO

US9221073052

Advanced Medical Equipment & Technology

Market Closed - OTC Markets 03:55:21 2024-04-15 pm EDT 5-day change 1st Jan Change
1.36 USD -15.00% Intraday chart for Vapotherm, Inc. -4.23% +36.00%
Sales 2022 66.8M Sales 2023 68.67M Capitalization 6.14M
Net income 2022 -113M Net income 2023 -58M EV / Sales 2022 2.42 x
Net Debt 2022 89.45M Net Debt 2023 103M EV / Sales 2023 1.58 x
P/E ratio 2022
-0.64 x
P/E ratio 2023
-0.1 x
Employees 182
Yield 2022 *
-
Yield 2023
-
Free-Float 83.21%
More Fundamentals * Assessed data
Dynamic Chart
Vapotherm, Inc. Enters into Amendment No. 7 to Loan and Security Agreement with SLR Investment Corp CI
Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE CI
Vapotherm, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vapotherm, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Vapotherm, Inc.(OTCPK:VAPO) dropped from S&P TMI Index CI
Vapotherm Says NYSE Suspends Its Shares' Trading Due to Non-Compliance With Market Capitalization Listing Rule MT
Top Premarket Decliners MT
Transcript : Vapotherm, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Vapotherm, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (VAPO) VAPOTHERM Posts Q3 Revenue $15.2M, vs. Street Est of $16.7M MT
Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023 CI
Vapotherm, Inc. Reiterates Revenue Guidance for the Full Year 2023 CI
Vapotherm, Inc. and its Chief Commercial Officer, Gregoire Ramade, Mutually Agreed to an Amicable Separation of Employment, Effective October 31, 2023 CI
Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023 CI
Vapotherm Shares Rise After Chief Executive Joseph Army Executes Stock Purchase MT
More news
1 day-10.63%
1 week+0.70%
Current month+8.33%
1 month+5.93%
3 months+49.72%
6 months-47.62%
Current year+43.00%
More quotes
1 week
1.28
Extreme 1.28
1.75
1 month
1.27
Extreme 1.27
1.75
Current year
0.75
Extreme 0.75
1.75
1 year
0.75
Extreme 0.75
7.44
3 years
0.75
Extreme 0.75
254.96
5 years
0.75
Extreme 0.75
435.36
10 years
0.75
Extreme 0.75
435.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 12-06-25
Director of Finance/CFO 52 12-07-31
Chief Tech/Sci/R&D Officer 54 21-12-05
Members of the board TitleAgeSince
Director/Board Member 70 20-10-20
Chairman 74 10-04-30
Director/Board Member 64 17-09-30
More insiders
Date Price Change Volume
24-04-15 1.36 -15.00% 834
24-04-12 1.6 +10.34% 3,650
24-04-11 1.45 -2.03% 8,510
24-04-09 1.48 +4.23% 1,746

Delayed Quote OTC Markets, April 15, 2024 at 10:41 am EDT

More quotes
Vapotherm, Inc. is a developer and manufacturer of advanced respiratory technology. It develops non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. It is focused on the care of patients suffering from respiratory distress, whether associated with lung diseases, such as chronic obstructive pulmonary disease, congestive heart failure, pneumonia, asthma, and COVID-19 or other systemic conditions. Its device solutions are focused on High Velocity Nasal Insufflation, which delivers non-invasive ventilatory support to patients by providing heated, humidified, oxygenated air at high velocities through a small-bore nasal interface, and on closed loop control systems, such as its Oxygen Assist Module, designed to automatically maintain a patients pulse oxygen saturation levels within a specified range for a defined period of time. Its digital solutions are focused on remote patient monitoring, using algorithms to predict respiratory episodes.
More about the company